

Anti-HER2/neu Reference Antibody (Zanidatamab)

Catalog # APR11610

Product Information

Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P04626
Reactivity	Human
Clonality	Bispecific
Isotype	Half IgG+ScFv
Calculated MW	137910


Additional Information

Target/Specificity	ERBB2 / HER2 / CD340
Expression system	CHO


Protein Information

Name	ERBB2
Synonyms	HER2, MLN19, NEU, NGL
Function	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
Cellular Location	Cell membrane; Single-pass type I membrane protein. Cell projection, ruffle membrane; Single-pass type I membrane protein. Note=Internalized from the cell membrane in response to EGF stimulation. [Isoform 2]: Cytoplasm. Nucleus.
Tissue Location	Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.


Images




Anti-HER2/neu Reference Antibody (Zanidatamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.




The purity of Anti-HER2/neu Reference Antibody (Zanidatamab) is 98.25%, determined by SEC-HPLC.




Zanidatamab bound to HER2 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Zanidatamab bound to hu-HER2-his, and the EC50 was 0.012 nM.



Zanidatamab bound to BT474 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcy PE) , and test by flow cytometry. As shown in fig, Zanidatamab bound to BT474 cells, and the EC50 was 3.061 nM.



Co-incubation of Zanidatamab with BT474 cell and PBMCs for 4 hours, then LDH was detected to evaluate the ADCC activity of Zanidatamab. As shown in fig, Zanidatamab has ADCC activity, and the IC50 was 0.023 nM.



The detected molecular weight of Anti-HER2/neu Reference Antibody (Zanidatamab) is 124.82 kDa.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.